Europe — EMA
Haemoctin Sdh (Human Coagulation Factor Viii)
Haemoctin Sdh is an EU‑approved intravenous human factor VIII solution for hemophilia A and von Willebrand disease type 3 treatment.
Request sourcing
What is Human Coagulation Factor Viii?
Haemoctin Sdh is a prescription solution for injection containing human coagulation factor VIII. It is supplied in an intravenous formulation and is used in the European market for the management of bleeding disorders. The product provides replacement therapy for patients with factor VIII deficiency, supporting the intrinsic pathway of the coagulation cascade. It is administered under medical supervision and stored according to manufacturer guidelines to maintain protein stability.
What is Human Coagulation Factor Viii used for?
Haemoctin Sdh is indicated for the replacement of deficient factor VIII in several clinical situations.
- Routine prophylaxis to prevent bleeding episodes in patients with severe hemophilia A. - On‑demand treatment of acute hemorrhage in hemophilia A. - Surgical or invasive procedure coverage to maintain hemostasis in hemophilia A patients. - Management of bleeding in von Willebrand disease type 3, which also lacks factor VIII.
What are the side effects of Human Coagulation Factor Viii?
Adverse reactions reported with Haemoctin Sdh reflect typical responses to factor VIII concentrates.
Common: - Headache. - Fever. - Nausea. - Injection‑site erythema. - Mild allergic rash.
Serious: - Anaphylactic reaction. - Development of inhibitors (neutralizing antibodies). - Thromboembolic events. - Severe hypotension. - Acute hemolysis (rare).
What precautions apply to Human Coagulation Factor Viii?
Before initiating therapy with Haemoctin Sdh, clinicians should evaluate several safety considerations.
- Assess patient history for prior inhibitor development. - Verify absence of active infections, especially hepatitis B/C or HIV. - Monitor for signs of hypersensitivity during and after infusion. - Use caution in patients with cardiovascular disease due to potential thrombotic risk. - Adjust dosage in pediatric patients based on weight and clinical response. - Store product at recommended temperature to preserve activity.
What does Human Coagulation Factor Viii interact with?
Haemoctin Sdh may interact with other agents that affect hemostasis or immune response.
Avoid: - Concurrent use of other factor concentrates without medical oversight. - High‑dose pro‑coagulant agents (e.g., activated factor VII) that could increase thrombosis risk.
Use with caution: - Immunosuppressive drugs that may alter inhibitor formation. - Antifibrinolytics (e.g., tranexamic acid) when combined with factor VIII therapy. - Vaccines administered shortly before or after infusion may affect immune response.
